Medical Treatments for Erectile Dysfunction

The 1980s viewed a progressive change away from psychological handling of sexual disorders to an emphasis on surgical and medical solutions for bettering sexual health. Simultaneously, there was a advanced change within the medical community and public at large, towards regarding the etiology of sexual disorders as organic, instead than the psychogenic understanding underlined by sex therapists. Practice of improved advanced diagnostic procedures, such as duplex sonography and cavernosograms (although not inevitably bettering treatment) brought credibleness and imprimatur to the importance of organic pathogenesis. This was especially true in the area of erectile dysfunction, where urologists established authority, with the prosperous marketing and practice of different intracavernosal and intraurethral systems. Although highly touted by urologists, the treatment efficaciousness of these products was offset by their intrusiveness into the patients bodies and decrease in spontaneity, their practices of practice needed.

Initially, there were few oral treatments for erectile dysfunction, being used by urologists, such as yohimbine based products, trazodone, and bupropion. They had only average proerectile capability. Pharmaceutical companies were inspired to pursue oral treatments with the hope of less intrusiveness and even better profits. The first available prove of meeting that anticipate was the sildenafil launch. Accompanying to Pfizers success, many companies at the same time followed clinical tests of easy-to-use treatments for male sexual disorders. Among others, these included supplemental PDE-5 type compounds and other oral treatments, such as ixense, and topically applied compounds. Additionally, PT-141 (Palatin Technology, Cranbury, NJ, USA) is a nasally administered peptide that is under development, which is assumed to work through a central nervous system mechanism.

Presently, there are three highly impelling PDE-5, FDA-approved treatments for erectile dysfunction: sildenafil, vardenafil, and tadalafil. Reviews of long-term extension analyses and published accounts of usage in clinical practice show that sildenafil's strength was maintained with long-term treatment. Significantly Combination Therapy for Sexual Dysfunction better erectile function was demonstrated for sildenafil compared with placebo for all efficacy parameters examined, regardless of patient age, race, body mass index, erectile dysfunction etiology, erectile dysfunction severity, erectile dysfunction duration, or the presence of several co morbidities. Long-term effectivity was evaluated in three open-label reference studies. Vardenafil (launched in 2003) is a potent, selective PDE-5 inhibitor, which improved erectile function in a general population of men with erectile dysfunction and in characteristically challenging-to-treat groups such as diabetic and post prostatectomy patients. Tadalafil also launched in 2003, when taken, as needed ahead sexual activity and without limitations on food or alcohol intake, significantly better erectile function. It provided a essential proportion of patients to reach a normal IIEF erectile function domain score, exposed a broad window of therapeutic reactivity and was well supported in a representative population of patients with broadspectrum erectile dysfunction.

About The Author

David Crawford is the CEO and owner of a Male Enhancement Products company known as Male Enhancement Group which is dedicated to researching and comparing male enhancement products in order to determine which male enhancement product is safer and more effective than other products on the market. Copyright 2010 David Crawford of http://www.maleenhancementgroup.com This article may be freely distributed if this resource box stays attached.

Diabetes is Not Always Permanent
Increasing The Insulin Output